Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radioiodine for Recurrent/Metastatic Thyroid Cancer
NCT03215095Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2017
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in thyroid cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose-Limiting Toxicity at 6 weeks. Started Jul 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT03215095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215095.